Arcus Biosciences Inc
NYSE:RCUS
Profitability Summary
Arcus Biosciences Inc's profitability score is 15/100. We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.
Score
We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.
We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.
Score
Score
Margins
Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.
Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Earnings Waterfall
Arcus Biosciences Inc
|
Revenue
|
258m
USD
|
|
Operating Expenses
|
-568m
USD
|
|
Operating Income
|
-310m
USD
|
|
Other Expenses
|
27m
USD
|
|
Net Income
|
-283m
USD
|
Margins Comparison
Arcus Biosciences Inc Competitors
| Country | Company | Market Cap |
Operating Margin |
Net Margin |
||
|---|---|---|---|---|---|---|
| US |
|
Arcus Biosciences Inc
NYSE:RCUS
|
955.1m USD |
-120%
|
-110%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-17 527%
|
-21 040%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
323.7B USD |
30%
|
7%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
146.1B USD |
25%
|
17%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
133.7B USD |
38%
|
21%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
112B USD |
38%
|
-9%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-370%
|
-392%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
119.3B AUD |
26%
|
18%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
63.7B USD |
29%
|
32%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
-33%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
37.8B USD |
-5%
|
-11%
|
Return on Capital
Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.
Return on Capital Comparison
Arcus Biosciences Inc Competitors
| Country | Company | Market Cap | ROE | ROA | ROCE | ROIC | ||
|---|---|---|---|---|---|---|---|---|
| US |
|
Arcus Biosciences Inc
NYSE:RCUS
|
955.1m USD |
-60%
|
-25%
|
-34%
|
-132%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
115%
|
-391%
|
275%
|
3 093%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
323.7B USD |
88%
|
3%
|
17%
|
20%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
146.1B USD |
106%
|
7%
|
12%
|
10%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
133.7B USD |
33%
|
11%
|
25%
|
19%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
112B USD |
-6%
|
-4%
|
21%
|
94%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-877%
|
-67%
|
-73%
|
-182%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
119.3B AUD |
15%
|
7%
|
12%
|
9%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
63.7B USD |
16%
|
13%
|
13%
|
14%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-28%
|
-21%
|
-27%
|
-39%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
37.8B USD |
519%
|
-7%
|
-4%
|
-6%
|
Free Cash Flow
Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.
If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.
You don't have any saved screeners yet
